About foghorn therapeutics inc - FHTX
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Watertown, MA.
FHTX At a Glance
Foghorn Therapeutics, Inc.
99 Coolidge Avenue
Watertown, Massachusetts 02472
| Phone | 1-617-586-3100 | Revenue | 30.91M | |
| Industry | Biotechnology | Net Income | -74,283,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 36.753% | |
| Fiscal Year-end | 12 / 2026 | Employees | 106 | |
| View SEC Filings |
FHTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.003 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.808 |
| Enterprise Value to Sales | 7.157 |
| Total Debt to Enterprise Value | 0.187 |
FHTX Efficiency
| Revenue/Employee | 291,594.34 |
| Income Per Employee | -700,783.019 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.072 |
FHTX Liquidity
| Current Ratio | 2.733 |
| Quick Ratio | 2.733 |
| Cash Ratio | 2.681 |
FHTX Profitability
| Gross Margin | 89.22 |
| Operating Margin | -265.641 |
| Pretax Margin | -240.328 |
| Net Margin | -240.328 |
| Return on Assets | -17.416 |
| Return on Equity | N/A |
| Return on Total Capital | 110.491 |
| Return on Invested Capital | N/A |
FHTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -61.386 |
| Total Debt to Total Assets | 10.457 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -60.013 |